Drawing for YUROXAN

USPTO serial 77942356

YUROXAN

Reviewed by CopyMark Law Group

Reg. 4040189Status 710
Filing date
Status date
Registration date
Oct 18, 2011
Examiner
CHOSID, ROBIN S
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with YUROXAN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and veterinary preparations for humans and animals, namely, medicines, vaccines, and serums for diagnostics, testing, prevention, treatment, and therapeutics, in particular medicines for treating cardiovascular illnesses, in particular hyperlipidaemia, coronary heart diseases and cardiac insufficiency; medicines for the treatment of immunological diseases, in particular autoimmune diseases in particular rheumatic disorders, polychondritis, Bechterew's disease, fibromyalgia and lupus erythematodes, rheumatoid arthritis, polyarthritis, Crohn's disease, and multiple sclerosis; medicines for treating skin diseases, in particular acne, actinic keratosis, alopecia, atopic dermatitis, Bowen's disease, cutaneous atopy, cutaneous T-cell lymphoma, Darrier's disease, Dartroud diathesis, dermatitis, eczema, genital herpes, genital warts, herpes, hyperkeratosis, hyperpigmentation, hyperplasia of the epidermis, hypopigmentation, ichthyosis, increased proliferation of skin cells, keloids, lentigo, lichen planus, melasma, molluscum contagiosum, mycosis fungoides, neoplasias, neurodermitis, pigmentation disorders, porokeratosis of Mibelli, psoriasis, removal of tattoos, rosacea, seborrhea, seborrheic keratosis, shingles, skin diseases related to inflammatory processes of skin cells, skin ulcers, vitiligo, warts, xerosis; medicines for treating tumourous diseases, in particular Astrocytomas, basal cell carcinomas, biliary cancers, bladder cancers, bone cancers, brain cancers, breast cancers, carcinomas, cervical cancers, cervical intraepithelial neoplasias, colorectal cancers, endocrine system cancers, ependymomas, epidermoid carcinomas, fibrosarcomas, gastric cancers, gastrointestinal cancers, glioblastomas, gynecologic cancers, head and neck cancers, hemangiomas, hepatomas, Hodgkin's lymphomas, Leukemia, liver cancers, lung cancers, lymphomas, medulloblastomas, meningiomas, mesothelaiomas, metastases, myelomas, neoplasias, neurectodermal cancers, neuroblastomas, neurofibromas, neurofibrosarcomas, neuronal cancers, non-Hodgkin's lymphomas, oligodendrogliomas, ovarian carcinoma, pancreatic cancers, pediatric cancers, penile cancer, pituitary adenomas, pleural cancers, renal cancer, sarcomas, Schwannomas, skin cancers, sqamous cell carcinomas, testicular cancers, thyroid cancers, thyroid tumors, urinary tract cancers, carcinoma of the prostate, melanoma, Kaposi's sarcoma, hepatocellular carcinoma; ALL OF THE ABOVE CONSISTING OF low-molecular active substances, liposomes, aptamers, nucleic acids, peptides, proteins, protein conjugates, antibodies, T-cell proteins, enzymes and enzyme preparations, hormones, hormone analogues, attenuated viruses, virus-type particles and plant extractsSECTION 8 - CANCELLED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 25, 2018C8..CANCELLED SEC. 8 (6-YR)
Oct 18, 2016REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 18, 2011R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 2, 2011NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 2, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 28, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 24, 2011ALIEASSIGNED TO LIE
Jun 22, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jun 22, 2011XAECEXAMINER'S AMENDMENT ENTERED
Jun 22, 2011GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 22, 2011GNEAEXAMINERS AMENDMENT E-MAILED
Jun 22, 2011CNEAEXAMINERS AMENDMENT -WRITTEN
Jan 3, 2011GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jan 3, 2011GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Jan 3, 2011CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Nov 29, 2010TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Nov 29, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 29, 2010TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 29, 2010GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 29, 2010GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 29, 2010CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 27, 2010DOCKASSIGNED TO EXAMINER
Mar 1, 2010NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 26, 2010NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance